PHVS PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

PHVS ▲ +3.32% at T+20d

SHORT call ✗ call lost -3.32% · α vs SPY -3.30% · entry $30.09 → $31.09

Next anchor: T+60d in 8w

Last close $31.59 (close Jun 8) · -4.99% from $30.09 entry (call sign-flipped)

Entry anchored
May 7, 03:59 PM ET
via Databento tick

T+1d

-0.47%

call +0.47% · α +0.70%

$29.95

settled 4w ago

T+5d

+2.03%

call -2.03% · α -0.56%

$30.70

settled 26d ago

T+20d

+3.32%

call -3.32% · α -3.30%

$31.09

settled yesterday

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Pharvaris priced a $115M underwritten offering of 3.87M shares at $29.68 per share, representing ~6% dilution. The capital raise funds late-stage HAE/AAE programs, but recent insider selling ($1.8M in 30 days) and dilution create near-term headwinds. The offering closes May 11, 2026.

Key Financial Metrics

Deal Value

$115.0M

Actionable Insight

The offering provides necessary capital for late-stage trials and potential NDA submission, but the dilution and insider selling are near-term negatives. Watch for the stock's reaction at open and any further insider transactions. The next major catalyst is CHAPTER-3 topline data in Q3 2026.

Key Facts

Priced 3,874,664 ordinary shares at $29.68 per share for gross proceeds of ~$115M
Underwriters have a 30-day option for up to 581,199 additional shares
Offering expected to close on or about May 11, 2026
Joint book-running managers: Morgan Stanley, Leerink Partners, Cantor, Wells Fargo Securities
Proceeds to fund clinical development and potential commercialization of deucrictibant for HAE and AAE-C1INH
Recent insider selling: 4 transactions totaling $1.8M in the past 30 days

Financial Impact

~6-7% dilution based on ~64M shares outstanding implied by $1.9B market cap at $29.68; gross proceeds of $115M

dilutioncash

Risk Factors

Dilution of ~6-7% reduces EPS and ownership for existing shareholders
Insider selling ahead of offering may signal lack of confidence
Clinical trial risks for deucrictibant (HAE/AAE programs)
Regulatory approval uncertainty for NDA submission planned in H1 2026

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

90% bullish (20 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3290920

23 reports for PHVS

T+1T+5T+20T+60

75% Hit rate 3 of 4 directional calls best @ T+20▲ +11.42%Mar 20, 2026

Filters

Reports for PHVS — sortable, filterable
	Type				Now
May 29, 2026 11d ago	Press Release NEUTRAL ★ 4/10	$30.16 $31.09	▲ +3.08%	▲ +5.61%	$31.59 (+4.74%)
May 26, 2026 14d ago	Insider Cluster NEUTRAL ★ 4/10	$29.47 $30.14	▲ +2.27%	▲ +1.80%	$31.59 (+7.19%)
May 26, 2026 14d ago	Insider Cluster BEARISH ★ 5/10	$29.47 $30.14	▼ −2.27%	▼ −1.80%	$31.59 (−7.19%)
May 22, 2026 18d ago	Insider Cluster NEUTRAL ★ 3/10	$29.68 $29.10	▼ −1.95%	▼ −3.63%	$31.59 (+6.44%)
May 21, 2026 19d ago	144 NEUTRAL ★ 3/10	$29.68 $29.10	▼ −1.95%	▼ −3.61%	$31.59 (+6.44%)
May 20, 2026 20d ago	Insider Cluster NEUTRAL ★ 3/10	$30.54 $30.16	▼ −1.24%	▼ −3.09%	$31.59 (+3.44%)
May 20, 2026 20d ago	144 NEUTRAL ★ 2/10	$30.54 $30.16	▼ −1.24%	▼ −3.09%	$31.59 (+3.44%)
May 19, 2026 21d ago	Insider Cluster NEUTRAL ★ 4/10	$29.45 $29.86	▲ +1.39%	▼ −0.41%	$31.59 (+7.27%)
May 12, 2026 28d ago	Press Release NEUTRAL ★ 5/10	$32.94 $28.95	▼ −12.11%	▼ −10.95%	$31.59 (−4.10%)
May 11, 2026 29d ago	6-K NEUTRAL ★ 4/10	$31.25 $28.81	▼ −7.81%	▼ −7.89%	$31.59 (+1.09%)

US Market Status

Market Closed — Opens in 7h 22m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access